Board changes at Pharmalink
This article was originally published in Scrip
Pharmalink has elected Anders Wiklund chair of its board of directors, and appointed Elisabeth Lindner a director. Pharmalink's founder and former chair Bengt Julander, and Lennart Hansson of Industrifonden remain on the board as non-executive directors. Mr Wiklund currently serves on the boards of QuatRx, EffRx, Clavis Pharma and Life Medical. Ms Lindner most recently served as president and CEO of Diamyd Medical and is a director at BioInvent International and Karo Bio, as well as the Royal Swedish Academy of Engineering Science.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.